AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20226404 — intervention group
Group type: COMPARATOR
Intervention: Ordinary laparoscopic cystectomy without injection
Number of subjects: 15
Study 20226404 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cystectomy with the injection of saline solution
Number of subjects: 15
Study 19112723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (starting dose 50 mg bid)
Number of subjects: 54
Study 19112723 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam (starting dose 0.5 mg qd)
Number of subjects: 54
Study 19112723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 54
Study 19112723 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 54
Study 16181303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg (once per day)
Number of subjects: 203
Study 16181303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 12719203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2501
Study 12719203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (low-risk patients)
Number of subjects: 2501
Study 12719203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (validation set low-risk patients)
Number of subjects: 2501
Study 12719203 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic oral anticoagulation therapy (low-risk patients)
Number of subjects: 2501
Study 10233567 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic drainage via the Freka(R) CystTUR Standard device
Number of subjects: 90
Study 10233567 — intervention group
Group type: EXPERIMENTAL
Intervention: Iglesias continuous‐flow resectoscope
Number of subjects: 90
Study 10233567 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic drainage using the Korth 'flow controller'
Number of subjects: 90
Study 8723141 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 23,884 monotherapy (3.5 +/- 0.5 mg)
Number of subjects: 7
Study 8723141 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 23,884 coadministered with a mildly dyskinetic dose of levodopa
Number of subjects: 7
Study 8723141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1885444 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive hypercapnia
Number of subjects: 7
Study 1885444 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory threshold loading (‐40 cmH2O)
Number of subjects: 7
Study 1885444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hypercapnia and loading
Number of subjects: 7
Study 6685515 — intervention group
Group type: EXPERIMENTAL
Intervention: oxazepam (Sigacalm)
Number of subjects: 14
Study 6685515 — intervention group
Group type: COMPARATOR
Intervention: standard oxazepam formulation
Number of subjects: 14
Study 30025745 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal prehabilitation (exercise, nutrition, anxiety-reduction) starting 4 weeks before surgery and continuing for 8 weeks after surgery.
Number of subjects: 139
Study 30025745 — intervention group
Group type: COMPARATOR
Intervention: Trimodal rehabilitation (identical to prehabilitation but initiated only after surgery).
Number of subjects: 139
Study 29344631 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) - 12 sessions, 60 minutes each
Number of subjects: 126
Study 29344631 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET) - 5 sessions, 60 minutes for the first session and 40 minutes for the remaining sessions
Number of subjects: 126
Study 29344631 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 126
Study 27220694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 12 weeks (1-week in-hospital training followed by 11-week outpatient program)
Number of subjects: 41
Study 27220694 — intervention group
Group type: COMPARATOR
Intervention: No intervention (non-CR group)
Number of subjects: 41
Study 25063985 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal meditation
Number of subjects: 123
Study 25063985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prenatal meditation)
Number of subjects: 123
Study 22431582 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (200 μg/m(3) of fine particulate matter) for 120 minutes
Number of subjects: 45
Study 22431582 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 45
Study 19190038 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach (Group I)
Number of subjects: 35
Study 19190038 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach (Group II)
Number of subjects: 35
Study 19190038 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach (Group III)
Number of subjects: 35
Study 17997151 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 300 mg tenofovir disoproxil fumarate with 200 mg emtricitabine
Number of subjects: 400
Study 17997151 — intervention group
Group type: COMPARATOR
Intervention: No study drug (control)
Number of subjects: 400
Study 17997151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 400
Study 17997151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 15486039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (45 mg)
Number of subjects: 24
Study 15486039 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 12214151 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20 mg quinapril for 6 months
Number of subjects: 60
Study 12214151 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-100 mg losartan for 6 months
Number of subjects: 60
Study 9825750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined step-down prednisolone, methotrexate and sulphasalazine
Number of subjects: 154
Study 9825750 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine alone
Number of subjects: 154
Study 7656941 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls in Peak Expiratory Flow (PEF) episodes
Number of subjects: 192
Study 7656941 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper and lower respiratory tract symptom events
Number of subjects: 192
Study 7656941 — intervention group
Group type: EXPERIMENTAL
Intervention: PEF episodes preceded by respiratory symptoms
Number of subjects: 192
Study 3053555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone + netilmicin
Number of subjects: 174
Study 3053555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin + netilmicin
Number of subjects: 174
Study 3053555 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin + netilmicin
Number of subjects: 174
Study 3053555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin + netilmicin
Number of subjects: 174
Study 3053555 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 174
Study 31982002 — intervention group
Group type: EXPERIMENTAL
Intervention: Random time session
Number of subjects: 15
Study 31982002 — intervention group
Group type: EXPERIMENTAL
Intervention: Random direction session
Number of subjects: 15
Study 31982002 — intervention group
Group type: COMPARATOR
Intervention: Constant session
Number of subjects: 15
Study 30973263 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic block to one finger
Number of subjects: 0
Study 30973263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile perceptual training during anesthetic block of the neighboring finger
Number of subjects: 0
Study 30973263 — intervention group
Group type: COMPARATOR
Intervention: Sham block with saline
Number of subjects: 0
Study 28777224 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intracameral bevacizumab
Number of subjects: 87
Study 28777224 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative mitomycin C (MMC)
Number of subjects: 87
Study 26646828 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy programme
Number of subjects: 34
Study 26646828 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 34
Study 23550668 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B plus flucytosine
Number of subjects: 299
Study 23550668 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B alone
Number of subjects: 299
Study 23550668 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B plus fluconazole
Number of subjects: 299
Study 23550668 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 299
Study 16943462 — intervention group
Group type: EXPERIMENTAL
Intervention: Palamed G
Number of subjects: 60
Study 16943462 — intervention group
Group type: COMPARATOR
Intervention: Palacos R with gentamicin
Number of subjects: 60
Study 14687360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 200
Study 14687360 — intervention group
Group type: COMPARATOR
Intervention: Computerized Balance Training (BT)
Number of subjects: 200
Study 14687360 — intervention group
Group type: COMPARATOR
Intervention: Education (ED)
Number of subjects: 200
Study 10809243 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate full-volume exchange (2000 mL) per 6 hours from the day of catheter implantation (group 2)
Number of subjects: 59
Study 10809243 — intervention group
Group type: COMPARATOR
Intervention: Stepwise volume increment method (group 1)
Number of subjects: 59
Study 10809243 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate full-volume exchange (group 2)
Number of subjects: 59
Study 8873503 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 40 mg/day
Number of subjects: 55
Study 8873503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 1516840 — intervention group
Group type: EXPERIMENTAL
Intervention: cold perfusate + EC‐SOD C 10.4 mg/L (30,000 U/L)
Number of subjects: 40
Study 1516840 — intervention group
Group type: COMPARATOR
Intervention: cold perfusate only
Number of subjects: 40
Study 1516840 — intervention group
Group type: COMPARATOR
Intervention: cold perfusate + bovine CuZn‐SOD 7.5 mg/L (30,000 U/L)
Number of subjects: 40
Study 1516840 — intervention group
Group type: COMPARATOR
Intervention: cold perfusate + EC‐SOD C 10.4 mg/L + heparin 50,000U/L
Number of subjects: 40
Study 1516840 — intervention group
Group type: COMPARATOR
Intervention: cold perfusate + heparin 50,000 U/L
Number of subjects: 40
Study 1516840 — intervention group
Group type: COMPARATOR
Intervention: cold perfusate only, cold perfusate + bovine CuZn‐SOD, cold perfusate + EC‐SOD C + heparin, cold perfusate + heparin
Number of subjects: 40
Study 6707844 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength cow's milk feeds after 24 hours of GEM treatment
Number of subjects: 48
Study 6707844 — intervention group
Group type: COMPARATOR
Intervention: Gradual reintroduction of milk over 4 days
Number of subjects: 48
Study 30362280 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Number of subjects: 201
Study 30362280 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 201
Study 30362280 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Number of subjects: 201
Study 30362280 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 201
Study 28857654 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine therapy for 12 weeks
Number of subjects: 23
Study 28857654 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 25670530 — intervention group
Group type: EXPERIMENTAL
Intervention: Acerto protocol
Number of subjects: 20
Study 25670530 — intervention group
Group type: COMPARATOR
Intervention: Traditional preoperative care
Number of subjects: 20
Study 23418947 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (11% O2) for 4 hours after a light breakfast
Number of subjects: 15
Study 23418947 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (control condition) for 4 hours after a light breakfast
Number of subjects: 15
Study 21299296 — intervention group
Group type: EXPERIMENTAL
Intervention: Group and individual exercise, moderate and challenging workouts (yoga, Pilates, aerobic exercise, weight training)
Number of subjects: 279
Study 21299296 — intervention group
Group type: EXPERIMENTAL
Intervention: Harnessing forecasting myopia
Number of subjects: 279
Study 21299296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcoming forecasting myopia
Number of subjects: 279
Study 19857180 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 50
Study 19857180 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and external fixation
Number of subjects: 50
Study 17284128 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 88
Study 17284128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (SSRI)
Number of subjects: 88
Study 17284128 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 88
Study 15041596 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincision ketamine 0.15 mg/kg
Number of subjects: 135
Study 15041596 — intervention group
Group type: COMPARATOR
Intervention: Postoperative ketamine 0.15 mg/kg
Number of subjects: 135
Study 15041596 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline IV
Number of subjects: 135
Study 11306778 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 37
Study 11306778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9483158 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trial (RCT) methodology
Number of subjects: 0
Study 9483158 — intervention group
Group type: COMPARATOR
Intervention: Cultural or religious objections to RCTs
Number of subjects: 0
Study 7942164 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 or 2000 mg Ca2+)
Number of subjects: 248
Study 7942164 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 248
Study 7942164 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 248
Study 2904754 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (mean dose, 3.3 mg) once daily for 8 weeks
Number of subjects: 40
Study 2904754 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg) once daily for 8 weeks
Number of subjects: 40
Study 29431256 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1322
Study 29431256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1322
Study 28628884 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 102
Study 26758116 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 2 mg/(kg·d) intravenously for 3 days
Number of subjects: 60
Study 26758116 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid therapy
Number of subjects: 60
Study 26758116 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 cases with bronchial foreign body, no respiratory tract infection)
Number of subjects: 60
Study 23768973 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 100
Study 23768973 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 100
Study 22028266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendrix (20 micrograms, 4 doses)
Number of subjects: 92
Study 22028266 — intervention group
Group type: COMPARATOR
Intervention: Engerix B (40 micrograms, 3 doses with optional booster)
Number of subjects: 92
Study 18081807 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha/Ketac‐Endo/cold lateral compaction
Number of subjects: 144
Study 18081807 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha/AH Plus/cold lateral compaction
Number of subjects: 144
Study 18081807 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany combinations
Number of subjects: 144
Study 18081807 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohesive failures
Number of subjects: 144
Study 16144849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium profiling (DC 15.0‐‐>14.0 mS/cm)
Number of subjects: 10
Study 16144849 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume (BV)-controlled feedback
Number of subjects: 10
Study 16144849 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-controlled feedback
Number of subjects: 10
Study 16144849 — intervention group
Group type: COMPARATOR
Intervention: Standard HD (dialysate conductivity DC 14.0 mS/cm)
Number of subjects: 10
Study 14629289 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of cyclosporine
Number of subjects: 56
Study 14629289 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of cyclosporine
Number of subjects: 56
Study 11185674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg QD for 10 days)
Number of subjects: 24
Study 11185674 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg once daily on days 4 through 10) with Rofecoxib
Number of subjects: 24
Study 11185674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 10 days)
Number of subjects: 24
Study 9174467 — intervention group
Group type: EXPERIMENTAL
Intervention: Emmental cheese
Number of subjects: 9
Study 9174467 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 9
Study 9174467 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium salt (calcium lactate gluconate + calcium carbonate)
Number of subjects: 9
Study 9174467 — intervention group
Group type: COMPARATOR
Intervention: Control session (no additional calcium)
Number of subjects: 9
Study 9174467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame seeds
Number of subjects: 9
Study 9174467 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 9
Study 1550149 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 140
Study 1550149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 1550149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 140
Study 2860386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg CL115,347/day transdermally for 6 weeks
Number of subjects: 29
Study 2860386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30624598 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month hypocaloric, nutritionally complete, higher-protein meal plan targeting ≥1.0 g protein · kg body weight-1 · d-1 (WL group; n=47)
Number of subjects: 96
Study 30624598 — intervention group
Group type: COMPARATOR
Intervention: Weight-stability (WS) group targeting 0.8 g protein · kg body weight-1 · d-1 (n=49)
Number of subjects: 96
Study 29739634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based exposure and response prevention (MB-ERP)
Number of subjects: 37
Study 29739634 — intervention group
Group type: COMPARATOR
Intervention: Exposure and response prevention (ERP)
Number of subjects: 37
Study 26993331 — intervention group
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine formulations (toxoids A and B) administered at antigen dose levels of 50, 100, or 200 μg in a 3-dose regimen at 0, 1, and 6 months.
Number of subjects: 0
Study 26993331 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 24495158 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 725
Study 24495158 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 725
Study 22782417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine (0.1 mg/kg per minute for 7 hours)
Number of subjects: 3080
Study 22782417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3080
Study 21311486 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (copaxone) 20 mg/d for 4.3±2.6 years
Number of subjects: 158
Study 21311486 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without MS)
Number of subjects: 158
Study 21311486 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with confirmed MS in remission not treated with disease-modifying drugs
Number of subjects: 158
Study 17433949 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary balloon angioplasty (PTCA)
Number of subjects: 1829
Study 17433949 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829
Study 17433949 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829
Study 17433949 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829
Study 16309127 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 220
Study 16309127 — intervention group
Group type: COMPARATOR
Intervention: Lofexidine hydrochloride (Control)
Number of subjects: 220
Study 12044618 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache pain during encoding
Number of subjects: 80
Study 12044618 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache pain during memory task
Number of subjects: 80
Study 12044618 — intervention group
Group type: COMPARATOR
Intervention: No headache pain during encoding
Number of subjects: 80
Study 12044618 — intervention group
Group type: COMPARATOR
Intervention: No headache pain during memory task
Number of subjects: 80
Study 10332798 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rehabilitation
Number of subjects: 59
Study 10332798 — intervention group
Group type: COMPARATOR
Intervention: Passive control treatment
Number of subjects: 59
Study 8949690 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% oxygen saturation (SpO2)
Number of subjects: 13
Study 8949690 — intervention group
Group type: COMPARATOR
Intervention: 90% oxygen saturation (SpO2)
Number of subjects: 13
Study 2044395 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg bencyclane twice daily
Number of subjects: 75
Study 2044395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 6796714 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposyn 10%
Number of subjects: 13
Study 6796714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 10%
Number of subjects: 13